Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine + Epcoritamab in Relapsed/Refractory DLBCL
2023-509861-19-00Phase 2Withdrawn
- Sponsor
- Universität Münster
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine and epcoritamab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma (FL), sponsored by Universität Münster. Primary endpoint: Best overall response rate (BORR) at 12 months. Planned start Apr 2025; status: withdrawn.
02
Drugs
loncastuximab tesirineepcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-509861-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509861-19-00.